Microbot Medical (NASDAQ: MBOT) awards CEO 480,000 stock options

Rhea-AI Filing Summary

Gadot Harel reported acquisition or exercise transactions in this Form 4 filing.

Microbot Medical Inc. reported that Chairman, President and CEO Harel Gadot received a grant of stock options covering 480,000 shares of common stock. These options were awarded under the company’s 2020 Omnibus Performance Award Plan.

According to the grant terms, 25% of the option vests and becomes exercisable on August 18, 2026. The remaining 75% vests and becomes exercisable in equal installments on a quarterly basis over the following 30 months, subject to the plan’s provisions on possible acceleration or forfeiture.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gadot Harel

(Last) (First) (Middle)

C/O MICROBOT MEDICAL INC.

175 DERBY ST., BLD. 27

(Street)

HINGHAM MA 02043

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Microbot Medical Inc. [ MBOT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chairman, President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/18/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.1	02/18/2026		A		480,000		(1)	02/18/2036	Common Stock, par value $0.01 per share	480,000	$0	480,000	D

Explanation of Responses:

1. The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan, as amended (the "Plan"): (a) on August 18, 2026, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock, subject to acceleration or forfeiture pursuant to the terms of the Plan.

	/s/ Harel Gadot	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Microbot Medical (MBOT) report for Harel Gadot?

Microbot Medical reported a grant of stock options to CEO Harel Gadot covering 480,000 shares of common stock. The options were awarded under the company’s 2020 Omnibus Performance Award Plan, reflecting equity-based executive compensation rather than an open-market share purchase or sale.

How many stock options were granted to the MBOT CEO in this Form 4?

The CEO of Microbot Medical received stock options for 480,000 shares of common stock. This entire amount represents a single award, with vesting scheduled over several years under the 2020 Omnibus Performance Award Plan, aligning executive incentives with longer-term company performance.

What is the vesting schedule for Harel Gadot’s 480,000 MBOT stock options?

The options vest in two phases: 25% of the 480,000-share grant vests and becomes exercisable on August 18, 2026. The remaining 75% vests in equal quarterly installments over the next 30 months, subject to potential acceleration or forfeiture under the plan’s terms.

Is the insider transaction in MBOT’s Form 4 a purchase or an award?

The reported transaction is an award of stock options, classified as a grant or other acquisition. It is not an open-market purchase or sale, but an equity compensation grant under Microbot Medical’s 2020 Omnibus Performance Award Plan to its Chairman, President and CEO.

Does Harel Gadot directly own the MBOT stock options reported in this filing?

Yes. The Form 4 shows the 480,000 stock options as directly owned by Harel Gadot. The ownership type is listed as direct, indicating the award is attributed personally to him rather than to an indirect entity such as a trust or partnership.

What plan governs the stock option award reported for MBOT’s CEO?

The stock option grant to Microbot Medical’s CEO is governed by the company’s 2020 Omnibus Performance Award Plan, as amended. The vesting schedule, exercisability, and any acceleration or forfeiture provisions follow the detailed terms set out in that compensation plan.